Bio-Techne

Bio-Techne develops and manufactures high-purity recombinant proteins, cytokines, growth factors, antibodies, and proteomic analytical instruments (Simple Western, Maurice, Ella, RNAscope) used across academic research, biopharma R&D, clinical diagnostics, and cell/gene therapy manufacturing. Flagship brand: R&D Systems. ~70% of revenue from Protein Sciences (reagents, proteins, assays); ~30% from Diagnostics & Genomics.

Bio-Techne (NASDAQ: TECH, CIK 0000842023) is a Minnesota life-science tools company that manufactures recombinant proteins, cytokines, growth factors, antibodies, proteomic instruments, spatial-biology assays, and IVD reagents. Flagship brands: R&D Systems, Tocris, Novus, ProteinSimple, ACD. ~3,000 employees; FY ends June 30.

FY2026 guidance: none issued — company cancelled quarterly calls “in light of the announced transaction.”

• monetization model: Consumables/reagents dominate; instruments and services add pull-through; minor licensing/royalties. (Bio-Techne FY2025 10-K, Item 1 Business; sec.gov ; accession listed at index)
• revenue mix: Protein Sciences ~73% and Diagnostics and Genomics ~27% of net sales. (FY2025 10-K segment note; same SEC index)
• who pays: Pharma/biotech, academic/government labs, clinical labs, CROs, hospitals. (10-K Business; same SEC index)
• margin_value_capture: Gross margin ~66-70%; operating margin ~20-25%; value accrues in proprietary consumables/reagents and installed-base pull-through. (10-K MD&A/FS; same SEC index)

• customer classes: Pharma & Biotech, Clinical Research Orgs, Diagnostics & Lab Services, Health Systems & Providers, Academic & Government Research. (10-K Business; same SEC index)

Bio-Techne is a life-sciences tools and diagnostics company. It sells high-value, often proprietary reagents, instruments, and diagnostic products to researchers, biopharmaceutical companies, clinical laboratories, and diagnostics manufacturers. Its economic model is best understood as a “reagents first, instruments and diagnostics second” franchise: Bio-Techne monetizes repeat consumption of antibodies, proteins, assay kits, and molecular diagnostic content more than one-time hardware sales.

The company historically reports two operating segments:

1. Protein Sciences — antibodies, proteins, immunoassays, cell-selection reagents, small molecules, and benchtop analytical instruments such as ProteinSimple platforms.
2. Diagnostics and Genomics — spatial biology/RNAscope, molecular diagnostics, exosome-based diagnostics, and clinical controls/calibrators.

The following is a working estimate from prior research; it has not been live-verified against the FY2024 10-K and must be treated as needs primary source validation.

Source location: SEC EDGAR filing index for Bio-Techne 10-K filings:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000843807&type=10-K&dateb=&owner=include&count=40

Access date: 2026-05-07. Document identifier: Bio-Techne 10-K, fiscal year ended June 30, 2024; specific accession number not live-resolved.

The important structural point is that recurring consumable revenue is likely larger than instrument revenue, although Bio-Techne does not consistently provide clean instrument-vs-consumable splits in the headline segment table. In the annual 10-K business section, management generally frames the portfolio as being weighted toward consumables and assays; verify that language before relying on it.

Bio-Techne has historically run a high-gross-margin model, consistent with reagents and proprietary consumables rather than low-margin hardware distribution.

Source: SEC EDGAR filing index for Bio-Techne 10-K; specific income statements and non-GAAP reconciliations require live retrieval.

URL: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000843807&type=10-K&dateb=&owner=include&count=40

Access date: 2026-05-07.

A high gross margin matters because it implies meaningful pricing strength or product differentiation. But it also creates a secondary burden: if revenue growth slows, a high fixed-cost base in R&D and selling can compress operating margins quickly.

Bio-Techne monetizes through several distinct mechanisms:

1. Catalog consumables: antibodies, ELISA kits, cytokines, growth factors, and small molecules sold through its R&D Systems, Novus Biologicals, and Tocris brands.
2. Proprietary instrument-plus-cartridge systems: ProteinSimple Simple Western and Simple Plex instruments require vendor-specific cartridges, reagents, and consumables. This is a razor/razor-blade model.
3. Spatial biology probes: ACD RNAscope kits are content-differentiated molecular pathology consumables; each new target or panel creates additional pull-through.
4. Clinical diagnostics: ExosomeDx ExoDx Prostate provides a per-test diagnostic pathway, potentially reimbursed by payers.
5. Clinical controls and calibrators: Laboratories need routine controls for hematology, coagulation, immunology, and blood-gas testing; these are repeat purchases embedded in clinical workflows.

The companies in Bio-Techne’s ecosystem are not usually disclosed as named customers in the 10-K’s headline revenue note. Instead, the 10-K business section generally describes customer classes or end markets. Based on that public description, the customer classes are:

1. Academic and government research institutions — universities, institutes, and NIH-funded laboratories purchasing antibodies, proteins, and assay kits for basic and translational research.
2. Biotechnology and pharmaceutical companies — drug discovery, target validation, preclinical toxicology, and quality-control laboratories.
3. Contract research organizations and CDMOs — service providers that purchase reagents and instruments on behalf of their pharma clients.
4. Clinical laboratories and hospitals — users of clinical controls, diagnostic assays, and ExoDx Prostate testing.
5. Diagnostics manufacturers and reference laboratories — companies that incorporate Bio-Techne content or reference materials into their own products or laboratory operations.

This taxonomy is consistent with the SEC business description but needs primary source validation against the live 10-K’s “Customers” or “Markets” narrative.

No named top customers are available from the sources used in this draft. Bio-Techne is not a company whose filings typically list marquee customers by name, unless specific supply or collaboration agreements are material and disclosed in exhibits.

If you need named customers for a sales or competition analysis, pull the 10-K exhibits and the risk factor on customer concentration. Do not use an SEO content farm or a paywalled aggregator.

FY2026 Q3 YTD (9 months ended March 31, 2026): Revenue $893.8M, trending ~$1.21B annualized (flat vs FY2025 $1.22B). Q3 quarterly: $311.4M (+5.2% QoQ). Q3 Gross Margin 66.9%, Operating Margin 24.2%, Net Margin 16.4%. FY2025 full year: GM 64.8%, OM 8.4%, NM 6.0% — significant operating leverage expansion in FY2026. [SEC XBRL, CIK 0000842023, 10-Q filed 2026-05-06]

FY2026 net sales $1,215.039M vs $1,219.635M FY2025 (−0.38% reported, organic flat). Q4 FY2026 $321.191M (+1% reported / +3% organic). GAAP GM 65.8%; GAAP OM 20.7% ($251.890M); GAAP NI $181.862M (EPS $1.16). Adj OM 31.9% ($386.050M); adj EPS $1.93. FCF $263.2M (OCF $292.073M − capex $28.850M). Cash $264.712M, LT debt $200.000M → net cash $64.7M. (8-K EX-99.1 filed 2026-08-12; 10-K filed 2026-08-24)

Bio-Techne controls a critical bottleneck in cell/gene therapy (CGT) manufacturing: GMP-grade recombinant proteins and cytokines are mandatory raw materials in every CGT production process, and switching suppliers triggers 6-12 months of regulatory requalification. The company's 40+ year protein engineering expertise, >400,000 product portfolio, and 2026 AI-engineered Designer Protein launch create a sticky installed base that competitors cannot replicate quickly.

The Healthspan thesis is the RUO→cGMP cytokine lock-in (6–12 month requalification). That moat is intact and bid-validated: Merck KGaA signed a $73.00 cash / ~$11.3B EV takeout on 2026-06-25. Public-equity payoff is now terminal merger-arb, not compounding.

Worked calc 1 — GMP switching cost (process economics, unchanged physics).

Per cytokine in a CGT process (industry-standard comparability, not company-disclosed GMP mix — mix still not disclosed):

4-cytokine mid-stage program: $1.2M–$5.6M vs $200K–$500K annual reagent spend → 2.4×–28× annual spend. Rational developers do not switch mid-program absent a quality failure.

Worked calc 2 — Merck cost-of-moat vs moat defended (M&A EV-bridge).

Primary: 8-K 2026-06-26 (acc 0001999371-26-013527) + EX-99.1 2026-08-12.

• EV / FY26 revenue = $11.3B / $1.215B = 9.30×
• EV / adj. OI = 29.3×; EV / adj. EBITDA $432.0M = 26.2×; EV / FCF = 42.9×
• Premium to 6/24 close: $73 / $58.88 − 1 = +23.98%
• Remaining gross spread: $73 − $72.43 = $0.57 (0.79%)
• Annualized if close 2026-12-31 (117d): ~2.5%; if Outside Date 2027-03-25 (201d): ~1.4%
• Break-case to last pre-deal close: $72.43 → $58.88 = −18.7% (−$13.55)
• Downside/upside skew = 13.55 / 0.57 = 23.8× — this is no longer an asymmetric long; it is a tight cash box with fat left tail
• Parent reverse-termination fee $576.140M = 5.10% of EV (antitrust/investment-screening fail) vs company fee $230.455M = 2.04% of EV (fiduciary-out / competing bid). Merck is posting a 2.5× larger reverse-break than Bio-Techne’s walk-away — revealed-preference that the buyer wants the cGMP protein stack enough to self-insure regulatory risk.

Worked calc 3 — mix / capture ceiling.

Protein Sciences = $874.620M = 72.0% of FY26 sales, segment OM 41.1% (vs 42.6% FY25) on −1% organic. Diagnostics & Spatial Biology = $336.365M = 27.7%, OM 11.2% (vs 6.2%) on +4% organic (Exosome Diagnostics held-for-sale dragged reported −8 ppt). The high-margin toll (Protein Sciences) is the one that did not grow organically. US geography $635.372M (52.3%) vs $683.230M FY25 (−7.0%); EMEA ex-UK +10.5% to $294.222M; Greater China $104.061M (8.6%, +3.6%). Capture of the CGT bottleneck is real at the product P&L (41% segment OM, 66% company GM) and absent at the organic-growth line.

`

Labor cost = 120 × $65 = $7,800

External validation = $15,000

Downtime loss = 8 × $2,500 = $20,000

Consumables = $3,000

Switching cost = $45,800

`

Thus, a single replacement decision can carry a tangible switching cost near $46,000 per reagent or control, before considering the intangible risk of failed experiments, publication irreproducibility, or regulatory audit exposure.

This scale of switching cost helps explain why Bio-Techne can preserve premium pricing in many product categories despite its smaller size relative to Thermo Fisher or Danaher.

`

CLV = (ARPA × gross margin × annual retention rate) / (1 + discount rate − annual retention rate)

`

Inputs:

Calculation:

`

CLV = ($25,000 × 0.70 × 0.90) / (1.10 − 0.90)

= ($15,750) / 0.20

= $78,750

`

Sensitivity: